A comprehensive review of present therapies of acanthosis nigricans

Acanthosis nigricans treatments



Acanthosis nigricans, insulin resistance, Diabetes Mellitus


BACKGROUND: Acanthosis nigricans (AN), marked by velvety skin plaques, signifies an underlying systemic disorder linked to rising obesity and diabetes rates. This study explores a comprehensive investigation of current AN treatment options, aiding clinicians in choosing effective and appropriate interventions for patients.

METHODS: A literature review was conducted using databases such as Google Scholar, PubMed, and MEDLINE, focusing on AN treatments in the last decade and totally 32 articles were evaluated.

RESULTS: Topical treatments, including retinoids, vitamin D analogs, keratolytics, and peels, are explored. Topical retinoids, especially tretinoin and adapalene, have demonstrated efficacy in clinical studies, while vitamin D analogs like calcipotriol show promise. Systemic treatments, such as oral retinoids (isotretinoin, acitretin, etretinate), insulin sensitizers (metformin, rosiglitazone), and other oral medications, are discussed. Metformin stands out for its effectiveness in treating AN associated with insulin resistance (IR). Cosmetic lasers, including alexandrite and carbon dioxide (CO2) lasers, offer successful outcomes in treating AN although cost and availability can be limiting factors. Other treatments, such as podophyllin, fish oil, photochemotherapy (PUVA), and surgery, are also considered.

CONCLUSION: AN necessitates a multifaceted approach, targeting both underlying systemic disorders and cosmetic concerns. The findings underscore the significance of topical treatments, systemic therapies like metformin, and the promising role of cosmetic lasers in AN management. Despite limitations in available studies, this comprehensive overview provides valuable insights for healthcare providers, emphasizing the need for personalized treatment strategies. As the prevalence of AN rises globally, continued research and clinical exploration are essential to refine and expand treatment options for this dermatological condition.


Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatology online journal. 2008;14(9).

Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. American journal of clinical dermatology. 2004;5:199-203.

Rendon MI, Cruz Jr PD, Sontheimer RD, Bergstresser PR. Acanthosis nigricans: a cutaneous marker of tissue resistance to insulin. Journal of the American Academy of Dermatology. 1989;21(3):461-9.

Phiske MM. An approach to acanthosis nigricans. Indian dermatology online journal. 2014;5(3):239.

Kutlubay Z, Engin B, Bairamov O, Tüzün Y. Acanthosis nigricans: A fold (intertriginous) dermatosis. Clinics in dermatology. 2015;33(4):466-70.

Das A, Datta D, Kassir M, Wollina U, Galadari H, Lotti T, et al. Acanthosis nigricans: a review. Journal of Cosmetic Dermatology. 2020;19(8):1857-65.

Popa M-L, Popa AC, Tanase C, Gheorghisan-Galateanu A-A. Acanthosis nigricans: To be or not to be afraid. Oncology letters. 2019;17(5):4133-8.

Puri N. A study of pathogenesis of acanthosis nigricans and its clinical implications. Indian Journal of Dermatology. 2011;56(6):678.

Patel NU, Roach C, Alinia H, Huang WW, Feldman SR. Current treatment options for acanthosis nigricans. Clinical, cosmetic and investigational dermatology. 2018:407-13.

Lahiri K, Malakar S. Topical tretinoin in acanthosis nigricans. Indian Journal of Dermatology, Venereology and Leprology. 1996;62(3):159-61.

Berger BJ, Gross PR. Another use for tretinoin—pseudoacanthosis nigricans. Archives of Dermatology. 1973;108(1):133-4.

Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Archives of dermatology. 1991;127(8):1139-40.

Schwartz RA. Efficacy of topical 0.1% adapalene gel for use in the treatment of childhood acanthosis nigricans: a pilot study. Dermatologic therapy. 2015;28(4):266.

Treesirichod A, Chaithirayanon S, Wongjitrat N, Wattanapan P. The efficacy of topical 0.1% adapalene gel for use in the treatment of childhood acanthosis nigricans: a pilot study. Indian Journal of Dermatology. 2015;60(1):103.

Treesirichod A, Chaithirayanon S, Wongjitrat N. Comparison of the efficacy and safety of 0.1% adapalene gel and 0.025% tretinoin cream in the treatment of childhood acanthosis nigricans. Pediatric Dermatology. 2019;36(3):330-4.

Treesirichod A, Chaithirayanon S, Chaikul T, Chansakulporn S. The randomized trials of 10% urea cream and 0.025% tretinoin cream in the treatment of acanthosis nigricans. Journal of Dermatological Treatment. 2021;32(7):837-42.

Weisshaar E, Bonnekoh B, Franke I, Gollnick H. Successful symptomatic tazarotene treatment of juvenile acanthosis nigricans of the familial obesity-associated type in insulin resistance. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2001;52(6):499-503.

Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. CUTIS-NEW YORK-. 2003;71(1):33-48.

Adigun C, Pandya A. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream. Journal of the European Academy of Dermatology and Venereology. 2009;23(4):486-7.

Binderup L, Bramm E. Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochemical pharmacology. 1988;37(5):889-95.

Romo A, Benavides S. Treatment options in insulin resistance obesity–related acanthosis nigricans. Annals of Pharmacotherapy. 2008;42(7-8):1090-4.

Böhm M, Luger T, Metze D. Treatment of mixed‐type acanthosis nigricans with topical calcipotriol. British Journal of Dermatology. 1998;139(5):932-4.

Lee H-W, Chang S-E, Lee M-W, Choi J-H, Moon K-C, Koh J-K. Hyperkeratosis of the nipple associated with acanthosis nigricans: treatment with topical calcipotriol. Journal of the American Academy of Dermatology. 2005;52(3):529-30.

Reyes-Meza SE, Guevara-Gutiérrez E, Villanueva-Quintero G, Hernández-Arana S, Tlacuilo-Parra A. Nevoid acanthosis nigricans: report of four cases localized to the umbilicus. Indian Journal of Dermatology, Venereology and Leprology. 2021;87(5):660-5.

Gregoriou S, Anyfandakis V, Kontoleon P, Christofidou E, Rigopoulos D, Kontochristopoulos G. Acanthosis nigricans associated with primary hypogonadism: successful treatment with topical calcipotriol. Journal of dermatological treatment. 2008;19(6):373-5.

Ehsani A, Noormohammadpour P, Goodarzi A, Shahshahani MM, Hejazi SP, Hosseini E, et al. Comparison of long-pulsed alexandrite laser and topical tretinoin-ammonium lactate in axillary acanthosis nigricans: A case series of patients in a before-after trial. Caspian journal of internal medicine. 2016;7(4):290.

Treesirichod A, Chuenboonngarm S, Kritsanaviparkporn C. The efficacy and safety of 20% urea cream and 10% urea cream in the treatment of acanthosis nigricans in adolescents, a randomized comparative double‐blind study. Journal of Cosmetic Dermatology. 2022;21(7):2859-64.

Treesirichod A, Thaneerat N, Kangvanskol W. A comparison of the efficacy and safety profiles of 10% salicylic acid and 10% urea creams in treating acanthosis nigricans in adolescents: a randomized double-blinded study. Archives of Dermatological Research. 2023:1-7.

Zayed A, Sobhi RM, Abdel Halim DM. Using trichloroacetic acid in the treatment of acanthosis nigricans: a pilot study. Journal of dermatological treatment. 2014;25(3):223-5.

Zaki NS, Hilal RF, Essam RM. Comparative study using fractional carbon dioxide laser versus glycolic acid peel in treatment of pseudo-acanthosis nigricans. Lasers in Medical Science. 2018;33(7):1485-91.

Bauer LB, Ornelas JN, Elston DM, Alikhan A. Isotretinoin: controversies, facts, and recommendations. Expert review of clinical pharmacology. 2016;9(11):1435-42.

Bagatin E, Costa CS. The use of isotretinoin for acne - an update on optimal dosing, surveillance, and adverse effects. Expert review of clinical pharmacology. 2020;13(8):885-97.

Jeong KH, Oh SJ, Chon S, Lee MH. Generalized acanthosis nigricans related to type B insulin resistance syndrome: a case report. Cutis. 2010;86(6):299-302.

Katz RA. Treatment of acanthosis nigricans with oral isotretinoin. Archives of Dermatology. 1980;116(1):110-1.

Walling HW, Messingham M, Myers LM, Mason CL, Strauss JS. Improvement of acanthosis nigricans on isotretinoin and metformin. Journal of Drugs in Dermatology: JDD. 2003;2(6):677-81.

Sriboonnark L, Arora H, Falto-Aizpurua L, Choudhary S, Connelly EA. Costello syndrome with severe nodulocystic acne: Unexpected significant improvement of acanthosis nigricans after oral isotretinoin treatment. Case Reports in Pediatrics. 2015;2015.

Swineford SL, Drucker CR. Palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis with retinoids. Journal of Drugs in Dermatology: JDD. 2010;9(9):1151-3.

Özdemi˙ r M, Toy Hc, Mevli˙ toğlu İ, Demi˙ rkesen C. Generalized idiopathic acanthosis nigricans treated with acitretin. Journal of dermatological treatment. 2006;17(1):54-6.

Skiljevic DS, Nikolic MM, Jakovljevic A, Dobrosavljevic DD. Generalized acanthosis nigricans in early childhood. Pediatric dermatology. 2001;18(3):213-6.

Pollock S, Swamy MR, Tremblay ES, Shen L. Acanthosis nigricans in the pediatric population: a narrative review of the current approach to management in primary care. Pediatric Medicine (Hong Kong, China). 2022;5:42-.

Akovbyan V, Talanin N, Arifov S, Tukhvatullina Z, Musabayev A, Baybekov I, et al. Successful treatment of acanthosis nigricans with etretinate. Journal of the American Academy of Dermatology. 1994;31(1):118-20.

Mørk N, Rajka G, Halse J. Treatment of acanthosis nigricans with etretinate (Tigason) in a patient with Lawrence-Seip syndrome (generalized lipodystrophy). Acta Dermato-Venereologica. 1986;66(2):173-4.

Baker H, Barth J. (46) Acanthosis nigricans. British Journal of Dermatology. 1983;109:101-3.

Ferrannini E. The target of metformin in type 2 diabetes. New England journal of medicine. 2014;371(16):1547-8.

Chang J-E, Choi MS. A molecular perspective on the potential benefits of metformin for the treatment of inflammatory skin disorders. International Journal of Molecular Sciences. 2020;21(23):8960.

Radu A-M, Carsote M, Dumitrascu MC, Sandru F. Acanthosis Nigricans: Pointer of Endocrine Entities. Diagnostics. 2022;12(10):2519.

Hermanns‐Lê T, Hermanns JF, Piérard GE. Juvenile acanthosis nigricans and insulin resistance. Pediatric dermatology. 2002;19(1):12-4.

Lee PJ, Cranston I, Amiel SA, O'Rahilly S, Green AA. Effect of metformin on glucose disposal and hyperinsulinaemia in a 14-year-old boy with acanthosis nigricans. Hormone Research in Paediatrics. 1997;48(2):88-92.

Bellot-Rojas P, Posadas-Sanchez R, Caracas-Portilla N, Zamora-Gonzalez J, Cardoso-Saldaña G, Jurado-Santacruz F, et al. Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. Journal of Drugs in Dermatology: JDD. 2006;5(9):884-9.

Tankova T, Koev D, Dakovska L, Kirilov G. Therapeutic approach in insulin resistance with acanthosis nigricans. International journal of clinical practice. 2002;56(8):578-81.

Wasniewska M, Arrigo T, Crisafulli G, Lombardo F, Messina M, Salzano G, et al. Recovery of acanthosis nigricans under prolonged metformin treatment in an adolescent with normal weight. Journal of endocrinological investigation. 2009;32:939-40.

Barbato MT, Criado PR, Silva AKd, Averbeck E, Guerine MB, Sá NBd. Association of acanthosis nigricans and skin tags with insulin resistance. Anais brasileiros de dermatologia. 2012;87:97-104.

Adderley-Rolle E, Peter S. Regression of acanthosis nigricans with the addition of sitagliptin and pioglitazone. The West Indian Medical Journal. 2015;64(2):160.

Sett A, Pradhan S, Sancheti K, Basu D, Datta A, Biswas L, et al. Effectiveness and safety of metformin versus Canthex™ in patients with acanthosis nigricans: A randomized, double-blind controlled trial. Indian Journal of Dermatology. 2019;64(2):115.

Lunetta M, Di Mauro M, Le Moli R, Burrafato S. Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. Journal of endocrinological investigation. 1996;19:699-703.

Sinha S, Schwartz RA. Juvenile acanthosis nigricans. Journal of the American Academy of Dermatology. 2007;57(3):502-8.

Sun H, Wang X, Chen J, Gusdon AM, Song K, Li L, et al. Melatonin treatment improves insulin resistance and pigmentation in obese patients with Acanthosis nigricans. International Journal of Endocrinology. 2018;2018.

Rosenbach A, Ram R. Treatment of acanthosis nigricans of the axillae using a long‐pulsed (5‐msec) alexandrite laser. Dermatologic surgery. 2004;30(8):1158-60.

Elmasry MF, Khalil MMF, Badawi A, Zaki NS, Fahim A. Efficacy of Fractional Carbon Dioxide (CO2) Laser versus Q-Switched Neodymium-Doped Yttrium Aluminum Garnet (Nd: YAG) and Potassium-Titanyl-Phosphate (KTP) Lasers in the Treatment of Acanthosis Nigricans. Clinical, Cosmetic and Investigational Dermatology. 2023:705-15.

Katz TM, Goldberg LH, Firoz BF, Friedman PM. Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation. Dermatologic surgery. 2009;35(11):1844-8.

Jacobs MA, Elston D, Cho S, editors. Acanthosis nigricans of the lips treated with carbon dioxide laser ablation. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY; 2011: MOSBY-ELSEVIER 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA.

Abu Oun AA, Ahmed NA, Hafiz HS. Comparative study between fractional carbon dioxide laser versus retinoic acid chemical peel in the treatment of acanthosis nigricans. Journal of Cosmetic Dermatology. 2022;21(3):1023-30.

Leerapongnan P, Jurairattanaporn N, Kanokrungsee S, Udompataikul M. Comparison of the effectiveness of fractional 1550-nm erbium fiber laser and 0.05% tretinoin cream in the treatment of acanthosis nigricans: a prospective, randomized, controlled trial. Lasers in Medical Science. 2020;35:1153-8.

Epstein E. Podophyllin therapy in acanthosis nigricans. The Journal of Investigative Dermatology. 1951;17(1):7-.

Huang TH, Wang PW, Yang SC, Chou WL, Fang JY. Cosmetic and Therapeutic Applications of Fish Oil's Fatty Acids on the Skin. Marine drugs. 2018;16(8).

Sherertz EF. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Archives of dermatology. 1988;124(7):1094-6.

Bonnekoh B, Thiele B, Merk H, Mahrle G. [Systemic photochemotherapy (PUVA) in acanthosis nigricans maligna: regression of keratosis, hyperpigmentation and pruritus]. Zeitschrift fur Hautkrankheiten. 1989;64(12):1059-62.

Schmolke B, Grotmann P, Kreusch J, Wolff HH. [Surgical therapy of lip involvement in acanthosis nigricans maligna]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 1994;45(12):875-7.

Butt NI, Mahmood K, Kanwal N, Ashfaq F. Acanthosis Nigricans in Patients with Type II Diabetes Mellitus at a Tertiary Care Hospital of Lahore. Journal of Bahria University Medical and Dental College. 2023;13(01):13-7.




How to Cite

Cheraghi M. A comprehensive review of present therapies of acanthosis nigricans: Acanthosis nigricans treatments. Chron Dis J. 2024;12(3).



Review Article(s)